PodcastRx with Chris Bender: November 2024

There's no better occasion than American Diabetes Month to dive into practical treatment recommendations for Type 2 diabetes. Using the ADA's Pharmacologic Approaches to Glycemic Treatment as a roadmap, Chris breaks down his clinical approach to 8 of the most common glucose-lowering medications. We also discuss the pharmacist recommendation process, correctional environment concerns, and benchmarks for patient success.

‍

Elsewhere in the show, we hear about:

Vlaylev and Orlynvah approvals for Parkinson's Disease and UTI treatments, respectively

Expanded Dupixent approval

New CDC COVID and pneumococcal vaccine recommendations

Rybelsus FLOW Trital results

The "Doggone" Discovery of Insulin

‍

Subscribe and listen on any major podcast platform, or listen right here.

‍

Links to material discussed in each segment:

‍

"Into the Clinic"

Vyalev Approved For Advanced Parkinson Disease

New Carbidopa/Levodopa Formulation Approved for Reducing OFF Time

Impax Pharmaceuticals Announce FDA Approval of RYTARY™ (Carbidopa and Levodopa) Extended-Release Capsules for the Treatment of Parkinson's disease‍

FDA approves new treatment for uncomplicated urinary tract infections in adult women who have limited or no alternative oral antibiotic treatment options

‍Dupixent Approved as Add-On Maintenance Therapy in COPD‍

CDC recommends 2nd COVID shot for some, lowering age for pneumococcal vaccination‍

Advisory Committee on Immunization Practices (ACIP) Recommendations

‍Novo Nordisk A/S: Oral semaglutide demonstrates a 14% reduction in risk of major adverse cardiovascular events in adults with type 2 diabetes in the SOUL trial

‍

Type 2 Diabetes Treatment Discussion

Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2024

‍

Trivia Capsule

The Discovery of Insulin

‍

‍

‍